BioInvent International AB
Clinical trials sponsored by BioInvent International AB, explained in plain language.
Biopharmaceutical company focused on antibody-based cancer immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug combo enters first human tests Results expected Jul 2027 (estimated)
-
New antibody combo shows promise in early cancer trial
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…
Phase 1/2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims to reboot immunotherapy in resistant cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…
Phase 1/2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC